
Cardiovascular & Metabolic Diseases
Breath biomarkers could lead to non-invasive detection and monitoring for liver disease, diabetes, kidney disease, heart failure and other cardiovascular and metabolic diseases
Find out more
Webinar: Identifying Translational Biomarkers using Breath Biopsy in vitro Headspace Analysis
A webinar introducing in vitro methods to investigate volatile metabolites as potential translational biomarkers
View Presentation
Article: Insights into potential VOC biomarkers of diabetes
Non-invasive breath testing offers an attractive alternative to currently available diabetes tests for diagnosis and ongoing monitoring
Read Review
Article: Examining candidate breath biomarkers for kidney disease
A non-invasive breath test could allow for cheaper screening and earlier intervention, when damage is less severe
View Publication
Case Study: Could acetone be a biomarker of heart failure?
Current biomarkers of heart function are very invasive but evidence suggests breath acetone could be useful for both diagnosis and prognosis
Read Case study
Paper: Breath Biopsy to identify exhaled VOCs as biomarkers for liver cirrhosis
A study to discover VOCs for early detection of progressive liver disease
VIEW PAPERIn developed countries, driven by poor diet and low exercise, fatty liver diseases have quietly reached epidemic levels across both adults and children. In the early stages, symptoms of liver disease are few, which is why the scale of the problem has gone largely unnoticed. With care the liver can heal itself, but without timely action liver damage can become permanent.
The economic impact of liver disease is enormous. For example, in the United States approximately 30% of US adults and as many as 1 in 10 children suffer from some form of liver disease, leading to direct and societal costs estimated at almost $300B per year. There is therefore an acute need for earlier detection when lifestyle changes and therapeutics can be effectively deployed, and the number of patients experiencing severe symptoms reduced.
We’ve worked on cardiovascular and metabolic disease with these groups:
Other recommended reading:
- POSTER: Pre-clinical in vitro VOC analysis to identify biomarker candidates for chronic liver diseases detection – A Breath Biopsy study.
- PAPER: Targeted breath analysis: exogenous volatile organic compounds (EVOC) as metabolic pathway-specific probes
- PAPER: VOCs from Exhaled Breath for the Diagnosis of Hepatocellular Carcinoma
- PAPER: Optimization of a breath analysis methodology to potentially diagnose transplanted kidney rejection
- PAPER: A deep learning approach for detecting liver cirrhosis from volatolomic analysis of exhaled breath
- PAPER: Visualization of exhaled breath metabolites reveals distinct diagnostic signatures for acute cardiorespiratory breathlessness
- REVIEW: Could breath acetone be a potentially useful biomarker for heart failure?
- POSTER: Comparing cirrhosis and liver cancers – A Breath Biopsy study with Cleveland Clinic proposing ketones and terpenes as possible biomarkers of chronic liver diseases
